These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 12921504)

  • 1. Severe hypersensitivity pneumonitis associated with anagrelide.
    Raghavan M; Mazer MA; Brink DJ
    Ann Pharmacother; 2003 Sep; 37(9):1228-31. PubMed ID: 12921504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 'Double hit' from streptococcal pneumonia and hypersensitivity pneumonitis associated with anagrelide.
    Spencer EM; Lawrence DS
    Clin Lab Haematol; 2006 Feb; 28(1):63-5. PubMed ID: 16430463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombocytosis--report of a case.
    Thomas M; Pavithran K; Salil ; Somarajan A
    J Assoc Physicians India; 2000 Apr; 48(4):441-2. PubMed ID: 11273186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxyurea-induced hypersensitivity pneumonitis: A case report and literature review.
    Sandhu HS; Barnes PJ; Hernandez P
    Can Respir J; 2000; 7(6):491-5. PubMed ID: 11121094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anagrelide is effective in treating patients with hydroxyurea-resistant thrombocytosis in patients with chronic myeloid leukemia.
    Silver RT
    Leukemia; 2005 Jan; 19(1):39-43. PubMed ID: 15510207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders.
    Birgegård G; Björkholm M; Kutti J; Lärfars G; Löfvenberg E; Markevärn B; Merup M; Palmblad J; Mauritzson N; Westin J; Samuelsson J
    Haematologica; 2004 May; 89(5):520-7. PubMed ID: 15136214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic myeloid leukaemia with marked thrombocytosis in a patient with thalassaemia major: complete haematological remission under the combination of hydroxyurea and anagrelide.
    Voskaridou E; Terpos E; Komninaka V; Eftyhiadis E; Mantzourani M; Loukopoulos D
    Br J Haematol; 2002 Jan; 116(1):155-7. PubMed ID: 11841409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment outcome of patients with essential thrombocythemia at our department in Hungary].
    Iványi JL; Marton É; Plander M; Szendrei T
    Orv Hetil; 2016 Feb; 157(9):336-41. PubMed ID: 26895801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Drug-induced interstitial pneumonitis in essential thrombocythemia treated with anagrelide].
    Kajiguchi T; Kamoshita S; Ito T; Yagi M; Kimura T
    Rinsho Ketsueki; 2017; 58(2):119-125. PubMed ID: 28321088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Precipitous fall in platelet count with anagrelide: case report and critique of dosing recommendations.
    McCune JS; Liles D; Lindley C
    Pharmacotherapy; 1997; 17(4):822-6. PubMed ID: 9250565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Combination of imatinib and anagrelide in treatment of chronic myeloid leukemia in blastic phase].
    Voglová J; Maisnar V; Beránek M; Chrobák L
    Vnitr Lek; 2006 Sep; 52(9):819-22. PubMed ID: 17091608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
    Harrison CN; Campbell PJ; Buck G; Wheatley K; East CL; Bareford D; Wilkins BS; van der Walt JD; Reilly JT; Grigg AP; Revell P; Woodcock BE; Green AR;
    N Engl J Med; 2005 Jul; 353(1):33-45. PubMed ID: 16000354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anagrelide for treatment of patients with chronic myelogenous leukemia and a high platelet count.
    Trapp OM; Beykirch MK; Petrides PE
    Blood Cells Mol Dis; 1998 Mar; 24(1):9-13. PubMed ID: 9516377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferative disorders.
    Balduini CL; Bertolino G; Noris P; Ascari E
    Haematologica; 1992; 77(1):40-3. PubMed ID: 1398280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anagrelide: new drug. Essential thrombocythaemia: further evaluation needed for this last-resort treatment.
    Prescrire Int; 2006 Jun; 15(83):83-6. PubMed ID: 16764090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Anagrelide Study Group.
    Am J Med; 1992 Jan; 92(1):69-76. PubMed ID: 1731512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders.
    Fruchtman SM; Petitt RM; Gilbert HS; Fiddler G; Lyne A;
    Leuk Res; 2005 May; 29(5):481-91. PubMed ID: 15755500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Anagrelide in control of myeloproliferative thrombocythemia: long-term experiences in 6 patients].
    Burkhard R; Adam H; Widmer L; Honegger HP
    Schweiz Med Wochenschr; 1998 Nov; 128(46):1808-12. PubMed ID: 9857387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anagrelide: 20 years later.
    Emadi A; Spivak JL
    Expert Rev Anticancer Ther; 2009 Jan; 9(1):37-50. PubMed ID: 19105705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anagrelide: what was new in 2004 and 2005?
    Petrides PE
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):399-408. PubMed ID: 16810615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.